Genzyme Convenes 13th European Fabry Disease Roundtable

  Genzyme Convenes 13th European Fabry Disease Roundtable

Business Wire

CAMBRIDGE, Mass. -- April 18, 2013

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that
the 13^th European Fabry Disease Roundtable will take place April 19 and 20 in
Madrid, Spain. The Roundtable is a scientific meeting sponsored by Genzyme
that brings together more than 200 participants from around the world,
including physicians, academics, researchers and patient organization
representatives to discuss current clinical care for patients with Fabry
disease and the future direction of disease management. This year’s Roundtable
is chaired by Franco Cecchi, MD, Professor of Cardiology, University of
Florence, Italy.

The theme of this year’s meeting is “Improving Specialized Care in Fabry
Disease,” with special focus on multidisciplinary care, and on new data and
insights regarding the diagnosis and management of patients with Fabry
disease.

“By providing a platform for both treating physicians and physicians who are
newer to Fabry disease, we have the opportunity to connect as a community to
learn from each other, sharing knowledge about the diagnostic process and the
clinical management of Fabry disease, with the goal to optimize patient care,”
said Dr. Cecchi. “I believe this will be an inspiring scientific event where
we will exchange and discuss clinical and scientific data that can be applied
in clinical practice.”

Among the topics for discussion:

  *Multidisciplinary care management in Fabry disease
  *Suspecting and diagnosing Fabry disease
  *New data regarding Genotypes and Phenotypes
  *Update on Fabry Disease Registry data
  *Trends in research
  *Biomarker identification

“The Fabry Disease Roundtable is a tremendous opportunity to bring together
thought leaders from around the world to exchange ideas, debate and further
increase our understanding of this disease,” said Genzyme’s Head of Rare
Diseases Rogerio Vivaldi, MD. “As we continue to better understand the optimal
way to care for patients who live with Fabry, there will be particular focus
on how adopting a multidisciplinary approach can improve treatment outcomes.”

About Fabry Disease

Fabry disease is caused by a genetic deficiency of an enzyme known as
alpha-galactosidase A or alpha-GAL, and is characterized by excessive
accumulation of the lipid GL-3 in various organs and tissues. Signs and
symptoms begin in childhood and lead to progressive life-threatening renal,
cardiac, and cerebrovascular complications. As a result, patients with Fabry
disease typically have a shortened life span, and children must often cope
with significant pain and disability. Fabry disease is a rare inherited
disease linked to the X chromosome and isestimated to affect roughly 1 in
117,000 people in the general population.

About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies
for patients affected by rare and debilitating diseases for over 30 years. We
accomplish our goals through world-class research and with the compassion and
commitment of our employees. With a focus on rare diseases and multiple
sclerosis, we are dedicated to making a positive impact on the lives of the
patients and families we serve. This goal guides and inspires us every day.
Genzyme’s portfolio of transformative therapies, which are marketed in
countries around the world, represents groundbreaking and life-saving advances
in medicine. As a Sanofi company, Genzyme benefits from the reach and
resources of one of the world’s largest pharmaceutical companies, with a
shared commitment to improving the lives of patients. Learn more at
www.genzyme.com.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients’ needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

Genzyme^® is the registered trademark of Genzyme Corporation. All rights
reserved.

Sanofi Forward Looking Statements

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product development
and potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words “expects”, “anticipates”,
“believes”, “intends”, “estimates”, “plans” and similar expressions. Although
Sanofi’s management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the availability or
commercial potential of such product candidates, the absence of guarantee that
the product candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group’s
ability to benefit from external growth opportunities, trends in exchange
rates and prevailing interest rates, the impact of cost containment policies
and subsequent changes thereto, the average number of shares outstanding as
well as those discussed or identified in the public filings with the SEC and
the AMF made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2012. Other than as
required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.

Contact:

Media Contact:
Genzyme
Lori Gorski, 617-768-9344
Lori.gorski@genzyme.com
 
Press spacebar to pause and continue. Press esc to stop.